Macrogen Inc (038290) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Macrogen Inc (038290) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.10 Billion ≈ $4.81 Million USD) by net assets (₩168.36 Billion ≈ $114.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Macrogen Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Macrogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 038290 liabilities breakdown for a breakdown of total debt and financial obligations.
Macrogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Macrogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nonthavej Hospital Public Company Limited
BK:NTV
|
0.041x |
|
Cube Entertainment Inc
KQ:182360
|
-0.108x |
|
Yuhwa Sec
KO:003460
|
0.183x |
|
Crossject
PA:ALCJ
|
2.893x |
|
Control Print Limited
NSE:CONTROLPR
|
0.065x |
|
Gan Shmuel
TA:GSFI
|
0.066x |
|
TOPMATERIAL LTD
KQ:360070
|
0.011x |
|
Vacasa Inc
NASDAQ:VCSA
|
-0.736x |
Annual Cash Flow Conversion Efficiency for Macrogen Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Macrogen Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 038290 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩177.43 Billion ≈ $120.24 Million |
₩7.12 Billion ≈ $4.83 Million |
0.040x | +34.13% |
| 2023-12-31 | ₩159.19 Billion ≈ $107.88 Million |
₩4.77 Billion ≈ $3.23 Million |
0.030x | -50.14% |
| 2022-12-31 | ₩179.32 Billion ≈ $121.52 Million |
₩10.77 Billion ≈ $7.30 Million |
0.060x | -43.13% |
| 2021-12-31 | ₩200.64 Billion ≈ $135.97 Million |
₩21.18 Billion ≈ $14.36 Million |
0.106x | +1.79% |
| 2020-12-31 | ₩198.15 Billion ≈ $134.28 Million |
₩20.55 Billion ≈ $13.93 Million |
0.104x | -18.91% |
| 2019-12-31 | ₩113.33 Billion ≈ $76.80 Million |
₩14.50 Billion ≈ $9.82 Million |
0.128x | -3.28% |
| 2018-12-31 | ₩118.01 Billion ≈ $79.98 Million |
₩15.61 Billion ≈ $10.58 Million |
0.132x | -4.58% |
| 2017-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩13.07 Billion ≈ $8.86 Million |
0.139x | -46.15% |
| 2016-12-31 | ₩82.55 Billion ≈ $55.94 Million |
₩21.25 Billion ≈ $14.40 Million |
0.257x | +173.79% |
| 2015-12-31 | ₩76.11 Billion ≈ $51.58 Million |
₩7.15 Billion ≈ $4.85 Million |
0.094x | -4.15% |
| 2014-12-31 | ₩67.13 Billion ≈ $45.49 Million |
₩6.58 Billion ≈ $4.46 Million |
0.098x | -35.74% |
| 2013-12-31 | ₩60.05 Billion ≈ $40.69 Million |
₩9.16 Billion ≈ $6.21 Million |
0.153x | -28.37% |
| 2012-12-31 | ₩51.71 Billion ≈ $35.05 Million |
₩11.02 Billion ≈ $7.47 Million |
0.213x | -17.57% |
| 2011-12-31 | ₩43.11 Billion ≈ $29.21 Million |
₩11.14 Billion ≈ $7.55 Million |
0.258x | -- |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more